Jefferies is maintaining its $36 PT on shares of Auxilium Pharmaceuticals, Inc. AUXL.
“Xiaflex continues to be the main stock driver for AUXL,” Jefferies writes. “We believe Xiaflex adoption is gated by reimbursement concerns rather than clinical concerns, and we anticipate steady Xiaflex sales growth in 2011 with sales acceleration in 2012.”
Auxilium Pharmaceuticals closed Friday at $22.32.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in